Literature DB >> 7937975

Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice.

G Schwab1, C Chavany, I Duroux, G Goubin, J Lebeau, C Hélène, T Saison-Behmoaras.   

Abstract

Ras oncogenes owe their transforming properties to single point mutations in the sequence coding for the active site of the p21 protein. These mutations lead to changes in cellular proliferation and induce tumorigenic properties. Point mutations represent a well-defined target for antisense oligonucleotides that can specifically suppress the translation of the targeted mutant mRNA. We show that the stability and cellular disponibility of antisense oligonucleotides can be markedly improved by adsorption to polyalkylcyanoacrylate nanoparticles. Nanoparticle-adsorbed antisense oligonucleotides directed to a point mutation (G-->U) in codon 12 of the Ha-ras mRNA selectively inhibited the proliferation of cells expressing the point-mutated Ha-ras gene at a concentration 100 times lower than free oligonucleotides. In addition they markedly inhibited Ha-ras-dependent tumor growth in nude mice after subcutaneous injection. These experiments show that inhibition of ras oncogenes by antisense oligonucleotides can block tumor development even though ras oncogenic activation might be an early event in tumor progression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7937975      PMCID: PMC45040          DOI: 10.1073/pnas.91.22.10460

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

Review 1.  ras oncogenes: their role in neoplasia.

Authors:  M Barbacid
Journal:  Eur J Clin Invest       Date:  1990-06       Impact factor: 4.686

Review 2.  Specific regulation of gene expression by antisense, sense and antigene nucleic acids.

Authors:  C Hélène; J J Toulmé
Journal:  Biochim Biophys Acta       Date:  1990-06-21

Review 3.  Inhibition of protooncogene expression by antisense oligodeoxynucleotides: biological and therapeutic implications.

Authors:  B Calabretta
Journal:  Cancer Res       Date:  1991-09-01       Impact factor: 12.701

4.  Antisense inhibition of ras p21 expression that is sensitive to a point mutation.

Authors:  E H Chang; P S Miller; C Cushman; K Devadas; K F Pirollo; P O Ts'o; Z P Yu
Journal:  Biochemistry       Date:  1991-08-27       Impact factor: 3.162

5.  Antibody targeted liposomes containing poly(rI).poly(rC) exert a specific antiviral and toxic effect on cells primed with interferons alpha/beta or gamma.

Authors:  P G Milhaud; P Machy; B Lebleu; L Leserman
Journal:  Biochim Biophys Acta       Date:  1989-12-11

6.  Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastasis-bearing mice.

Authors:  N Chiannilkulchai; N Ammoury; B Caillou; J P Devissaguet; P Couvreur
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 7.  ras oncogenes in human cancer: a review.

Authors:  J L Bos
Journal:  Cancer Res       Date:  1989-09-01       Impact factor: 12.701

8.  Constitutive overexpression of a 89 kDa heat shock protein gene in the HBL100 human mammary cell line converted to a tumorigenic phenotype by the EJ/T24 Harvey-ras oncogene.

Authors:  J Lebeau; C Le Chalony; M T Prosperi; G Goubin
Journal:  Oncogene       Date:  1991-07       Impact factor: 9.867

9.  Doxorubicin-loaded nanoparticles: increased efficiency in murine hepatic metastases.

Authors:  N Chiannilkulchai; Z Driouich; J P Benoit; A L Parodi; P Couvreur
Journal:  Sel Cancer Ther       Date:  1989

10.  Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation.

Authors:  T Saison-Behmoaras; B Tocqué; I Rey; M Chassignol; N T Thuong; C Hélène
Journal:  EMBO J       Date:  1991-05       Impact factor: 11.598

View more
  17 in total

Review 1.  Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway.

Authors:  D W End
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 2.  Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides.

Authors:  R L Juliano; S Alahari; H Yoo; R Kole; M Cho
Journal:  Pharm Res       Date:  1999-04       Impact factor: 4.200

3.  The spherulites(TM): a promising carrier for oligonucleotide delivery.

Authors:  N Mignet; A Brun; C Degert; B Delord; D Roux; C Hélène; R Laversanne; J C François
Journal:  Nucleic Acids Res       Date:  2000-08-15       Impact factor: 16.971

Review 4.  Nanocarriers' entry into the cell: relevance to drug delivery.

Authors:  Hervé Hillaireau; Patrick Couvreur
Journal:  Cell Mol Life Sci       Date:  2009-06-05       Impact factor: 9.261

Review 5.  Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA.

Authors:  Elias Fattal; Gillian Barratt
Journal:  Br J Pharmacol       Date:  2009-04-02       Impact factor: 8.739

6.  Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides.

Authors:  G Lambert; E Fattal; H Pinto-Alphandary; A Gulik; P Couvreur
Journal:  Pharm Res       Date:  2000-06       Impact factor: 4.200

7.  Pharmacokinetics and biodistribution of oligonucleotide adsorbed onto poly(isobutylcyanoacrylate) nanoparticles after intravenous administration in mice.

Authors:  Y Nakada; E Fattal; M Foulquier; P Couvreur
Journal:  Pharm Res       Date:  1996-01       Impact factor: 4.200

8.  Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: dependence on phosphorothioate modification and reversal by heparin.

Authors:  G Hartmann; A Krug; K Waller-Fontaine; S Endres
Journal:  Mol Med       Date:  1996-07       Impact factor: 6.354

9.  Rational design of point mutation-selective antisense DNA targeted to codon 12 of Ha-ras mRNA in human cells.

Authors:  I Duroux; G Godard; M Boidot-Forget; G Schwab; C Hélène; T Saison-Behmoaras
Journal:  Nucleic Acids Res       Date:  1995-09-11       Impact factor: 16.971

Review 10.  Nanotechnology: intelligent design to treat complex disease.

Authors:  Patrick Couvreur; Christine Vauthier
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.